Section Review—Oncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer

References

• HARRIS CC: Molecular basis of multistage carcinogene- sis. In: Multistage Carcinogenesis. Harris CC, Hirohashi S, Ito N, Pitot !IC, Sugimura T, Terada M, Yokota J (Eds.). Japan Sci. Soc. Press, Tokyo/CRC Press, Boca Raton (1992):3–19.
   Google Scholar
• WEINBERG RA: Oncogenes, tumour suppressor genes, and cell transformation: trying to put it all together. In: Origins of Human Cancer A Comprehensive Review. Brugge J, Curran T, Harlow ED, and McCormick F (Eds.). Cold Spring Harbor Laboratory Press, New York (1991):1–16.
   Google Scholar
• STEIN CA, COHEN JS: Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. (1988) 48:2659-2668. A detailed review of oligodeoxynucleotides as inhibitors of gene expression.
   Google Scholar
• HANVEY JC, PEFFER NJ, BISI JE, THOMPSON SA, CADILLA R, JOSEY JA, RICCA DJ, HASSMAN CF, BONIIAM MA, AU KG, CARTER SG, BRUCKENSTEIN DA, BOYD AL, NOBLE SA, BABISS LE: Antisense and antigene properties of peptide nucleic acids. Science (1992) 258:1481–1485.
   PubMed Web of Science ®Google Scholar
• CHOO Y, SANCHEZ-GARCIA I, KLUNG A: In vivo repres-sion by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature (1994) 372:642–645
   PubMed Web of Science ®Google Scholar
• MERCOLA D, COHEN JS: Antisense approaches to cancer gene therapy. Cancer Gene Ther. (1995) 2:47-59. A recent review on antisense approaches to cancer gene therapy.
   Google Scholar
• CROOKE ST: Oligonucleotide therapeutics: a prospec-tus. Antisense Res. Develop. (1993) 3:1–2.
   PubMedGoogle Scholar
• WICKSTROM E: Oligodeoxynucleotide stability in sub-cellular extracts and culture media. J. Biochem. Biophys. Methods (1986) 13:97–102.
   PubMedGoogle Scholar
• HELENE C: Rational design of sequence-specific onco-• gene inhibitors based on antisense and antigene oli- gonucleotides. Eur. J. Cancer (1991) 27:1466-1471. A good review about design of sequence-specific oncogene inhibi-tors based on antisense and antigene oligonucleotides.
   Google Scholar
• CROOKE RM: In vitro toxicology and phammcoldnetics of antisense oligonucleotides. Anti-Cancer Drug Design (1991) 6:609–646.
   PubMedGoogle Scholar
• PROCHOWNIK EV- Antisense approaches to assessingoncogene signaling pathway. In: Gene Regulation: Biol-ogy of Antisense RNA and DNA. Erickson RP, Izant JG (Eds.). Raven Press Ltd., New York (1992) 1:303–316.
   Google Scholar
• STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004-1012. A good discussion on the basic science and application of oligos as therapeutic agents.
   Google Scholar
• SZCZYL1K C, SKORSK1 T, NICOLAIDES NC, MANZELLA L, MALAGUARNERA L, VENTURELLI D, GEWIRTZ AM, CALABREI1 A B: Selective inhibition of leukemia cellproliferation by BCR-ABL antisense oligodeoxynu-cleotides. Science (1991) 253:562–565.
   PubMedGoogle Scholar
• SKORSKI T, NIEBOROWSKASKORSKA M, BARLETTA C, MALAGUARNERA L, SZCZYLIK C, CHEN ST, LANGE B, CALABRETTA B: Highly efficient elimination of Philadel-phia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with Mafosfamide. Clitz. Invest. (1993) 9:194–202.
   Google Scholar
• AlcliTAR S, IVINSON AJ: Therapies that make sense. Nature Genet. (1993) 4:215–217.
   PubMed Web of Science ®Google Scholar
• BAYEVER E, IVERSEN P, SMITH L, SPINOLO J, ZON G: Guest editorial: systemic human antisense therapy begins. Antisense Res. Dev. (1992) 2:109–110.
   PubMedGoogle Scholar
• SMITH U, MCCULLOCH EA, BENCHIMOL 5: Expression ofthe p53 oncogene in acute myeloblastic leukemia./ Exp. Med. (1986) 164:71–76.
   Google Scholar
• MAHER LJ, DOLNICK BJ: Specific hybridization arrest of dihydrofolate reductase mRNAin vitro using anti-sense RNA or anti-sense oligonucleotides. Arch. Biochem. Bio-phys. (1987) 253:214–220.
   PubMed Web of Science ®Google Scholar
• WALDER RY, WALDER JA: Role of RNase H in hybrid-ar-rested translation by antisense oligonudeotides. Proc. Natl. Acad. Sci. USA (1988) 85:5011–5015.
   PubMed Web of Science ®Google Scholar
• LOKE SL, STEIN C, ZHANG X1-1, MORI K, NAKANISHI M,SUBASINGHE C, COHEN JS, NECKERS LM: Charac-terization of oligonudeotide transport into living cells. Proc. Natl. Acad. Sci. USA (1989) 86:3474–3478.
   PubMed Web of Science ®Google Scholar
• YAKUBOV LA, DEEVA EA, ZARYTOVA VF, IVANOVA EM,RYTE AS, YURCIIENKO LV, VLASSOV VV: Mechanism of oligonucleotide uptake by cells: involvement of recep-tors? Proc. Natl, Acad. Sci. USA (1989) 86:6454–6458.
   PubMed Web of Science ®Google Scholar
• STEIN CA, TONKINSON JL, ZIIANG LM, YAKL1130V L, GERVASONI J, TAUB R, ROSENBERG SA: Dynamics of the Internalization of phosphodiester oligodeoxynu-cleotides in HL60 cells. Biochemistry (1993) 32:4855–4861.
   PubMed Web of Science ®Google Scholar
• AKHTAR 5, SHOJI Y, JULIANO RL: Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense. In: Gene Regulation: Biology of Antisense RNA and DNA. Erickson RP, Izant JG (Eds.). Raven Press Ltd., New York (1992) 1:133–145.
   Google Scholar
• SHAW JP, KENT K, BIRD J, FISHBACK J, FROEHLER B:Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. (1991) 19:747–750.
   PubMed Web of Science ®Google Scholar
• LETSINGER RL, ZHANG G, SUN DK, IKEUCHI T, SARIN PS:Cholesteryl-conjugated oligonucleotides: synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in culture. Proc. Natl. Acad. Sci. USA (1989) 86:6553–6556.
   PubMed Web of Science ®Google Scholar
• CLARENCE JP, DEGOLS G, LEONETTI JP, MILHAUD P,LEBLEU B: Delivery of antisense oligonucleotides by poly (L-lysine) conjugation and liposome encapsula-tion. Anti-Cancer Drug Design (1993) 8:81–94.
   PubMedGoogle Scholar
• LEONETTI JP, MACHY P, DEGOLS G, LEBLEU B, LESERMAN L: Antibody-targeted liposomes containing oligode-oxyonucleotides complementary to viral RNA selec-tively inhibit viral replication. Proc. Natl. Acad. Sci. USA (1990) 87:2448–2451.
   PubMed Web of Science ®Google Scholar
• MILLIGAN JF, JONES RJ, FROEHLER BC, MA! 1EUCCI MD:Development of antisense therapeutics: Implications for cancer gene therapy. Annals New York Acad. Sci. (1994) 716:228–241.
   PubMed Web of Science ®Google Scholar
• EGUCHI Y, ITOH T, TOMIZAWA J: Antisense RNA. Ann.
   Google Scholar
• •Rev. Biochem. (1991) 60:631-652. A thorough review on antisense RNA.
   Google Scholar
• !CRYSTAL GW: Regulation of eukaryotic gene expression by naturally occurring antisense RNA. In: Gene Regula-tion: Biology of Antisense RNA and DNA. Erickson RP, Izant JG (Eds.). Raven Press Ltd., New York. (1992) 1:11–20.
   Google Scholar
• INOUYE M: Antisense RNA: its function and applications in gene regulation - A review. Gene (1988) 72:25-34. A review of antisense RNA function and its applications in gene regulation.
   Google Scholar
• WEINTRAUB HM: Antisense RNA and DNA. Sci. Am. (1990) 262:40–48.
   Google Scholar
• LEDWITH BJ, MANAM S, KRAYNAK AR, NICHOLS WW, BRADLEY MO: Antisense-fos RNA causes partial rever-sion of the transformation phenotypes induced by the c-Ha-ras oncogene. Mol. Cell. Biol. (1990) 10:1545–1555.
   PubMed Web of Science ®Google Scholar
• SKLAR MD, THOMPSON E, WELSH MJ, LIEBERT M, HARNEYJ, GROSSMAN HB, SMITH M, PROCHOWNIK EV: Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIB 3T3 cells. Mol. Cell. Biol. (1991) 11:3699–3710.
   PubMed Web of Science ®Google Scholar
• MUKHOPADHYAY T, TAINSKY M, CAVENDER AC, ROTHJA: Specific inhibition of K-ras expression and tu-morigenicity of lung cancer cells by antisense RNA. Cancer Res. (1991) 51:1744–1748.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, MUKI-I0EADIIYAY T, DONEHOWER LA, GEOR-GES RN, ROTH JA: Retroviral vector-mediated transduc-tion of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Tber. (1993) 4:451–460.
   PubMed Web of Science ®Google Scholar
• GEORGES RN, MUKHOPATAIYAY T, ZHANG Y, YEN N,ROTI I JAL: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral an-tisense K-ras construct. Cancer Res. (1993) 53:1743–1746.
   PubMed Web of Science ®Google Scholar
• KIBLER-HERZOG L, KELL B, ZON G, SHINOZUKA K, MII-ZAN S, WILSON WD: Sequence-dependent effects in methylphosphonate deoxyribonucleotide double and triple helical complexes. Nucleic Acids Res. (1990) 18:3545–3555.
   PubMed Web of Science ®Google Scholar
• MAHER U, WOLD B, DERVAN PB: Inhibition of DNA s binding proteins by oligonucleotide-directed triple he-lix formation. Science (1989) 245:725-730. First report of inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation.
   Google Scholar
• HANVEY JC, SHIMIZU M, WELLS RD: Site-specific inhibi-tion of EcoRI restriction/modification enzymes by a DNA triple helix. Nucleic Acids Res. (1990) 18:157–161.
   PubMed Web of Science ®Google Scholar
• COONEY M, CZERNUSZEWICZ G, POSTEL EH, FLINT SJ, HOGAN ME: Site-specific oligonucleotide binding re-presses transcription of the human c-myc gene in vitro. Science (1988) 241:456-459. First report of site-specific oligonucleotide binding represses tran-scription of the human c-myc gene in vitro.
   Google Scholar
• ORSON FM, THOMAS DW, MCSIIAN WM, KESSLER DJ, TIOGAN ME, Oligonucleotide inhibition of IL2Ra RNA transcription by promoter region collinear triplex for-mation in lymphocytes. Nucleic Acids Res. (1991) 19:3435–3441.
   PubMed Web of Science ®Google Scholar
• GEE JE, MILLER DM: Structure and applications of inter-• molecular DNA triplexes. Am. J. Med. Sci. (1992) 304:366-372. A detailed review of structure and applications of intermolecular DNA triplexes.
   Google Scholar
• ONO A, TS'0 OP, KAN LS: Triplex formation of oligonu-cleotides containing 2'-0-methylpseudo-isocytidine in substitution for 2'-deoxycytidine. J. Am, Chem. Soc. (1991) 113:4032–4033.
   Web of Science ®Google Scholar
• GAGNOR C, BERTRAND JR, THENET S, LEMAITRE M, MOR-VAN F, RAYNER B, MALVY C, LEBLEU B, IMBACH JL, PAOLETTI C: Comparative study of a and 13 anomeric oligodeoxy-ribonucleotides in hybridization to mRNA and in cell-free translation inhibition. Nucleic Acids Res. (1987) 15:10507–10521.
   PubMedGoogle Scholar
• HELENE C: Control of gene expression by antisense andantigene oligonucleotide-intercalator conjugates. In: Gene Regulation: Biology of Antisense RNA and DNA. Erick-son RP, Izant JG (Eds.). Raven Press Ltd., New York (1992) 1:109–118.
   Google Scholar
• KIM SH, CECH TR: Three-dimensional model of the active site of the self-splicing rRNA precursor of Tetra-hymena. Proc. Natl. Acad. Sci. USA (1987) 84:8788-8792. First report on the three-dimensional model of the active site of ribozymes.
   Google Scholar
• CECH TR: Ribozymes and their medical implications. /A11'IA (1988) 260:3030–3034.
   PubMed Web of Science ®Google Scholar
• VON AIISEN U, SCHROEDER R: RNA as a catalyst: natural A thorough review on RNA as a catalyst: natural and designed ribozymes.
   Google Scholar
• KASHANI-SABET M, FUNATO T, TONE T, JIAO L, WANG W, YOSHIDA E, KASIIFINN BI, SHITARA T, WU AM, MORENO JG, TRAWEEK ST, AHLERING TE, SCANLON KJ: Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dee. (1992) 2:3-15. A significant report on reversal of the malignant phenotype by an anti-oncogene ribozyme.
   Google Scholar
• KOIZUMI M, KAMIYA H, OHTSUKA E: Mbozymes de-signed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene (1992) 117:179–184.
   PubMed Web of Science ®Google Scholar
• SIOUD M, NATVIG JB, FORRE 0: Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J. Mol. Biol. (1992) 223:831–835.
   PubMed Web of Science ®Google Scholar
• WEERASINGHE M, LLEM SE, ASAD S, READ SE, JOSIII S:Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived canines conferred by using retroviral vectors express-ing an HIV-1 RNA-specific ribozyme. J. Virol. (1991) 65:5531–5534.
   PubMed Web of Science ®Google Scholar
• LC D, CHAI1ERJEE S, BRAR D, WONG KK, Jr.: Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papil-lomavirus type 16. Cancer Gene Ther. (1994) 1:267–277.
   PubMed Web of Science ®Google Scholar
• HARRIS H: How tumour suppressor genes were discov- ered. FASEB J. (1993) 7:978-979. A thorough review on discovery of tumour suppressor genes.
   Google Scholar
• ANDERSON MJ, STANBRIDGE EJ: Tumour suppressor genes studied by cell hybridization and chromosome transfer. FASEB J. (1993) 7:826–833.
   PubMed Web of Science ®Google Scholar
• DONEHOWER LA, HARVEY M, SLAGLE BL, MCARTHUR MJ, MONTGOMERY CA, BUTEL JS, BRADLEY A: Mice deficient forp53 are developmentally normal but susceptible to spontaneous tumors. Nature (1992) 356:215-221. First report of the model of p53 deficient transgenic mouse.
   Google Scholar
• WIMAN KG: The retinoblastoma gene: role in cell-cycle control and cell differentiation. EASEBJ(1993) 7:841-845. A detailed review about the role of Rb gene in cell-cycle control and cell differentiation.
   Google Scholar
• HUANG HJS, YEE JK, SHEW JY, CHEN PL, BOOKSTEIN R, •FRIEDMANN T, LEE EYHP, LEE WIT: Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science (1988) 242:1563-1566. A significant report of the tumor suppressor activity of the Rb gene.
   Google Scholar
• BOOKSTEIN R, SHEW JY, CITEN PL, SCULLY P, LEE WH: •Suppression of tumorigenicity of human prostate car-cinoma cells by replacing a mutated Rb gene. Science (1990) 247:712-715. First report of suppression of tumourigenicity by restoring a wild type Rb gene.
   Google Scholar
• MONTENARTI M: Biochemical, immunological, and functional aspects of the growth-suppressor/oncopro-tein p53. Crit. Rev. Oncog. (1992) 3:233-256. A thorough review of p53 in biochemical, immunological, and functional aspects.
   Google Scholar
• TOMINAGA 0, HAMELIN R, REMVIKOS Y, SALMON RJ, THOMAS G: p53 from basic research to clinical applica-tions. Crit. Rev. Oncog. (1992) 3:257–282.
   PubMedGoogle Scholar
• MERCER WE: Cell-cycle regulation and the p53 tumour suppressor protein. Crit. Rev. Eukaryot. Gene Expr. (1992) 2:251–263 and deciotteri rihn 7srmec_ RinFccnan (1QQA1 1 4. 200- Afr and designed ribozymes. BioEssays (1993) 15:299–307.
   PubMedGoogle Scholar
• KUERBITZ SJ, PLUNKETT BS, WALSH WV, KASTAN MB: Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA (1992) 89:7491–7495.
   PubMed Web of Science ®Google Scholar
• FIELDS S, JANG SJ: Presence of a potent transcription-ac- tivating sequence in the p53 protein. Science (1990) 249:1046-1049. First report of presence of a potent transcription-activating sequence in the p53 protein.
   Google Scholar
• MIETZ JA, UNGER T, HUIBREGTSE JM, HOWLEY PM: The transcriptional trans activation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. (1992) 11:5013–5020.
   PubMed Web of Science ®Google Scholar
• WILCOCK D, LANE DP: Localization of p53, retinoblas- toma, and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 349:429-431. A significant report of involvement of the p53 and RB proteins in DNA replication.
   Google Scholar
• BARGONETFI J, FRIEDMANN PN, KERN SE, VOGELSTEIN B, PRIVES C: Wild-type but not mutant p53 immunopu-rifled proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 65:1083–1091.
   PubMed Web of Science ®Google Scholar
• YONISH-ROUACH E, RESNITZKY D, LOTEM J, SACHS L, KIMCHI A, OREN M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (1991) 352:345-347. First report of the p53 protein as an inducer of apoptosis.
   Google Scholar
• SHAW P, BOVEY R, TARDY S, SAIILI R, SORDAT B, COSTA J: Induction of apoptosis by wild-type p53 in a human colon tumour-derived cell line. Proc. Natl. Acad. Sci. USA (1992) 89:4495–4499.
   PubMed Web of Science ®Google Scholar
• RYAN JJ, DANIII R, GOI ILIEB CA, CLARKE M: Cell-cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell. Biol. (1993) 13:711–719.
   PubMed Web of Science ®Google Scholar
• FINLAY CA, HINDS PW, LEVINE AJ: The p53 proto-onco- •gene can act as a suppressor of transformation. Cell(1989) 57:1083-1093. A significant report of the p53 protein as a tumour suppressor.
   Google Scholar
• BAKER SJ, MARKOWITZ S, FEARSON ER, VILLSON JICV, VOGELSTEIN B: Suppression of human colorectal carci-noma cell growth by wild-type p53. Science (1990) 249:912-915. First report of tumour suppressor activity of the wild-type p53 gene.
   Google Scholar
• CHENG J, YEE JK, YEARGIN J, FRIEDMANN T, HAAS M: Suppression of acute lymphoblastk leukemia by the human wikl-typep53 gene. CancerRes. (1992) 52:222–226.
   Web of Science ®Google Scholar
• TAKAHASHI T, CARBONE D, TAKAHASHI T, NAU MM, HIDA T, LINNOILA I, UEDA R, MINNA JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. (1992) 52:2340–2343.
   PubMed Web of Science ®Google Scholar
• QUINLAN DC, DAVIDSON AG, SUMMERS CL, WARDEN HE,DOSHI HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. (1992) 52:4828–4831.
   PubMed Web of Science ®Google Scholar
• HORIO Y, TAKAHASHI T, KUROISHI T, HIBI K, SUYAMA M, NIIMI T: Prognostic significance ofp53 mutations and 3P deletions in primary resected non-small cell lung cancer. Cancer Res. (1993) 53:1–4.
   PubMed Web of Science ®Google Scholar
• SHRIVASTOVA S, ZOLI A, PIROLLO K, BLATTNER S, CHANGE: Germline transnassion of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome. Na-ture (1990) 348:747–749.
   PubMed Web of Science ®Google Scholar
• HARPER JW, ADAM GR, WEI N, KEYOMARSI K, ELLEDGE SJ: The p21 Cdk-interacting protein Cipl is a potent Inhibitor of G1 cyclin-dependent kinase. Cell (1993) 75:805-816. A significant report of identification of the p21 protein as an inhibitor of G1 cyclin-dependent kinase.
   Google Scholar
• EL-DEIRY WS, TOKINO T, VELCULESCU YE, LEVY DB, PARSONS R, TRENT JM, UN D, MERCER WE, KINZ1ER KW, VOGELSTEIN B: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75:817-825. First report on WAEI, a potential mediator of p53 tumour suppres-sion.
   Google Scholar
• ROEMER K, FRIEDMANN T: Mechanisms of action of thep53 tumour suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Annals New York Acad. Sci. (1994) 716:265–280.
   PubMed Web of Science ®Google Scholar
• GOYETTE MC, CHO K, FASCHING CL, LEVY DB, KINZLERKW, PARASKEVA C, VOGELSTEIN B, STANBRIDGE EJ: Progression of colorectal cancer is associated with multiple tumour suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol. (1992) 12:1387–1395.
   PubMed Web of Science ®Google Scholar
• LEONE A, FLATOW U, KING CR, SANDEEN MA, MARGULIES MK, LIOTIA LA, STEEG PS: Reduced tumour incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell (1991) 65:25-35. A significant report of the tumour suppression activity of nin23.
   Google Scholar
• FLORENES VA, AAMDAL S, MYKLEBOST 0, MAELANDSMO GM, BRULAND OS, FODSTAD 0: Levels of tun23 messen-ger RNA in metastatic melanomas inverse correlation to disease prognosis. Cancer Res. (1992) 52:6088–6091.
   PubMed Web of Science ®Google Scholar
• KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, •HARSHMAN K, TAVTIGIAN SV, STOCKERT E, DAY RS III,JOHNSON BE, SKOLNICK Mil: A cell cycle regulator potentially involved in genesis of many tumour types. Science (1994) 264:436-440. First report of p16 and p15 as major tumour suppressors (MTS).
   Google Scholar
• NOBORI T, MIURA K, WU DJ, LOIS A, TAKABAYASIII K, CARSON DA: Deletions of the cyclin-dependent kinase-4 Inhibitor gene in multiple human cancers. Nature(1994) 368:753–756.
   PubMed Web of Science ®Google Scholar
• MIKI Y, SWENSEN J, SHATTUCK-EIDENS D, FUFREAL PA, •HARSHMAN K, TAVTIGIAN S, LIU Q, COCHRAN C, BEN- NETT LM, DING W, BELL R, ROSENTHAL J, HUSSEY C, TRAN T, MCCLURE M, FRYE C, HATTIER T, PHELPS R, I IAUGEN-STRANO A, 'CATCHER H, YAKUMO K, GHOLAMI Z, SHAF-FER D, STONE S, BAYER 5, WRAY C, BOGDEN R, DAYANANTH P, WARD J, TONIN P, NAROD S, BRISTOW PK, NORRIS FH, HELVERING L, MORRISON P, ROSTECK P, LAI M, BARRETT JC, LEWIS C, NEUHAUSEN S, CANNON-AL-BRIGHT L, GOLDGAR D, WISEMAN R, KAMB A, SKOLNICK MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCAl. Science (1994) 266:66–
   Google Scholar
• First report of identification of the BRCAI gene.
   Google Scholar
• HANNON G, BEACH D: p15INK4B is a potential effector of TGF-I3-induced cell cycle arrest. Nature (1994) 371:257–261.
   PubMed Web of Science ®Google Scholar
• MARX J: A challenge to pI6 gene as a major tumoursuppressor. Science (1994) 264:1846. SO
   Google Scholar
• ZHANG S-Y, KLEIN-SZANTO AJP, SAUTER ER, SHA-FARENKO M, MITSLINAGA S. NOBORI T, CARSON DA, RIDGE JA, GOODROW TL: Higher frequency of alterna-tions in the pl 6/CDKN2 gene in squamous cell carci-noma cell lines than in primary tumours of the head and neck. Cancer Res. (1994) 54:5050–5053.
   Google Scholar
• JEN J, HARPER W, BIGNER SH, BIGNER DD, PAPADOPOU-LOS N, MARKOWITZ S, WILLSON JK V, KINZLER KW, VOGELSTEIN B: Deletion of p16 and p15 genes in brain tumors. Cancer Res. (1994) 54:6353–6358.
   PubMed Web of Science ®Google Scholar
• WASHIMI 0, NAGATAKE M, OSADA H, UEDA R, KOSILIKAWA T, SET(' T, TAKAHASHI T, TAKAHASHI T: In vivo occurrence ofp /6 (MTSI) and p15 (MTS2) altera-tions preferentially in non-small cell lung cancers. Cancer Res. (1995) 55:514–517.
   PubMed Web of Science ®Google Scholar
• HUSSUSSIAN g, STRUEWING JP, GOLDSTEIN AM, HIG-GINS PAT, ALLY DS, SHEAHAN MD, CLARK WH JR, TUCKER MA, DRACOPOLI NC: Germlinep/6 mutation in familial melanoma. Nature Genet. (1994) 8:15–21.
   PubMedGoogle Scholar
• CAI D W, MUKHOPADINAY T, LIU Y, FUJI WARA T, ROTHJA: Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Human Gene Ther. (1993) 4:617–624.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, GRIMM EA, MUKHOPADHYAY T, CAI DW,OWEN-SCHAUB LB, ROTH JA: A retroviral wild-type p53 expression vector penetrates human lung cancer sphe-roids and inhibits growth by inducing apoptosis. Can-cer Res. (1993) 53:4129–4133.
   PubMed Web of Science ®Google Scholar
• CASSON AG, MUICHOPADIIYAY T, CLEARY KR, RO JY,LEVINE B, ROTH JA: p53 mutations in Barrett's epithe-lium and esophageal cancer. Cancer Res. (1991) 51:4495–4499.
   PubMed Web of Science ®Google Scholar
• CHUNG KY, MUKHOPADIIYAY T, KIM J, CASSON A, RO JY, GOEPFERT H, HONG WK, ROTH JA: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the aerodi-gestive tract. Cancer Res. (1993) 53:1676–1683.
   PubMed Web of Science ®Google Scholar
• ZHANG W-W, FANG X, BRANCH CD, MAZUR W, FRENCH BA, ROTH JA: Generation and identification of recombi-nant adenovirus by liposome-mediated transfection and PCR analysis. BioTechniques (1993) 15:868-872. First report of generation of recombinant p53 adenovirus.
   Google Scholar
• ZHANG W-W, FANG X, MAZUR W, FRENCH BA, GEORGES RN, ROTH JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. (1994) 1:5-13. A significant report of the recombinant p53 adenovirus and its application in lung cancer suppression.
   Google Scholar
• WANG J, I3UCANA CD, ROTH JA, ZHANG W-W: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMVp53. Cancer Gene Ther. (1995) 1:9–17.
   Google Scholar
• WILLS KN, MANE VAL DC, MENZEL P, HARRIS MP, SUTJIPTO S, VAILLANCOURT M-T, HUANG W-M, JOHNSON DE, AN-DERSON SC, WEN SF, BOOKSTEIN R, SHEPARD HM, GRE-GORY RJ: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Ther. (1994) 5:1079–1088.
   PubMed Web of Science ®Google Scholar
• LIU TJ, ZHANG W-W, TAYLOR DL, ROTH JA, GOEPFERT H, CLAYMAN GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. (1994) 54:3662–3667.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Drug sensitivity ('suicide') genes for se-lective cancer chemotherapy. Cancer Gene Ther. (1994) 1:279–287.
   PubMed Web of Science ®Google Scholar
• MAXWELL III, MAXWELL F, GLODE LM: Regulated expres-sion of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Res. (1986) 46:4660–4664.
   PubMed Web of Science ®Google Scholar
• BREITMAN M L, CLAPOFF 5, ROSSANT J, TSUI L C, GLODE • LM, MAXWELL IH, BERNSTEIN A: Genetic ablation: pro-grammed lineage suicide by tissue-specific expression of the diphtheria toxin A gene in transgenic mice. Science (1987) 238:1563-1565. First report of tissue-specific expression of a toxin gene in vivo.
   Google Scholar
• PALMITER RD, BEHRINGER RR, QUAIFE CJ, MAXWELL F, MAXWELL III, BRINSTER RL: Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell (1987) 50:435–443.
   PubMed Web of Science ®Google Scholar
• YAMAIZUMI M, MEKADA E, UCHIDA T, OKADA Y: One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell (1978) 15:245–250.
   PubMed Web of Science ®Google Scholar
• MAXWELL IH, GLODE LM, MAXWELL F: Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-Iymphoid malignancy. Leuk. Lymphoma (1992) 7:457–462.
   PubMed Web of Science ®Google Scholar
• PURI RIC, OGATA M, LELAND P, FELDMAN GM, FITZGER-ALD D, PASTAN 1: Expression of high-affinity inter-lenient 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumour cells to chimeric protein between interleukin 4 and Pseudo-monas exotoxin. Cancer Res. (1991) 51:3011–3017 .
   PubMed Web of Science ®Google Scholar
• RAO L, DEBBAS M, SABBATINI P, HOCKENBERY D, KORS-MEYER S, WHITE E: The adenovirus ElA proteins induce apoptosis which is inhibited by the ElB 19K and Bc1-2 proteins. Proc. Natl. Acad, Sci. USA (1992) 89:7742–7746.
   PubMed Web of Science ®Google Scholar
• DEBBAS M, WHITE E: Wild-type p53 mediates apoptosis by ElA which is inhibited by ElB. Gene Dee. (1993) 7:546–554.
   PubMed Web of Science ®Google Scholar
• VU D, WOLF JK, SCANLON M, PRICE JE, HUNG MC: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by ElA. Canc. Res. (1993) 53:891–898.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, VU D, X1A W, HUNG MC: HER-2/neu-targeting cancer therapy via adenovirus-mediated ElA delivery in an animal modeL Oncogene (1995). In press.
   Google Scholar
• ELION GB, FURMAN PA, FYFE JA, DE MIRANDA P, BEAUCHAMP L, SCIIAEFFER HJ: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyDgua-nine. Proc. Natl. Acad. Sci. USA (1977) 74:5716–5720.
   PubMed Web of Science ®Google Scholar
• DAVIDSON RE, KAUFMAN ER, CRUMPACKER CS, SCHNIP- PER LE: Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: mecha- nisms of uptake and toxicity. Virology (1981) 113:9-19. A mechanism study of acycloguanosine as anti-FISV agent.
   Google Scholar
• MOOLTEN FL, WELLS JM: Curability of tumours bearing herpes thymidine kinase genes transferred by retrovi-rad vectors. J. Natl. Cancer Inst. (1990) 82:297–300.
   PubMed Web of Science ®Google Scholar
• CULVER KW, RAM Z, WALLBRIDGE S, ISHII TI, OLDFIELD EH, BLAESE EM: Vector-producer cells for treatment of experimental brain tumours. Science (1992) 256:1550-1552. A significant report of treatment of brain tumour model with HSV-tk gene transfer with systemic administration of GCV.
   Google Scholar
• BI WL, TARYSEK LM, WARNICK R, STAMBROOK PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Human Gene Ther. (1993) 4:725–731.
   PubMed Web of Science ®Google Scholar
• OLDFIELD EH: Gene therapy for the treatment of brain tumours using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Human Gene Ther. (1993) 4:36–69.
   Google Scholar
• HUBER BE, RICHARDS CA, KRENITSKY TA: Retroviral-me- diated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl, Acad. Sci. USA (1991) 88:8039-8043. A significant report of design of tissue-specific expression of a prodrug-activation gene for gene therapy of cancer.
   Google Scholar
• MUM EN CA, KILSTRUP M, BLAESE RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl. Acad. Sci. USA (1992) 89:33–37.
   PubMed Web of Science ®Google Scholar
• GARVER RI, Jr., GOLDSMITH KT, RODU B, HU PC, SOR-SCHER EJ, CURIEL DT: Strategy for achieving selective killing of carcinomas. Gene Ther. (1994) 1:46–50.
   PubMed Web of Science ®Google Scholar
• MANOME Y, ABE M, HAGEN MF, FINE HA, KUFE DW: Enhancer sequences of the DF3 gene regulate expres-sion of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. (1994) 54:5408–5413.
   PubMed Web of Science ®Google Scholar
• SMITH MJ, ROUSCULP MD, GOLDSMITH KT, CURIEL DT, GARVER RI, Jr.: Surfactant protein A-directed toxin gene kills lung cancer cells in vivo. Human Gene Ther. (1994) 5:29–35.
   Google Scholar
• DIMAIO JM, CLARY BM, VIA DF, COVENEY E, PAPPAS TN, LYERLY HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery (1994) 116:205–213.
   PubMed Web of Science ®Google Scholar
• WEI M-X, TAMIYA T, CHASE M, BOVIATSIS EJ, CHANG TKH, KOWALL NW, HOCHBERG PH, WAXMAN DJ, BREAKEFIELD XO, CHIOCCA EA: Experimental tumor therapy in mice using the cyclophosphamide-activat-ing cytochrome P450 2B1 gene. Human Gene Ther. (1994) 5:969–978.
   PubMed Web of Science ®Google Scholar
• WEICHSELBAUM RR, HALLAHAN DE, BECKETT MA, MAUCER1 HJ, LEE H, SUKHATME VP, KLTE DW: Gene therapy targeted by by radiation preferentially ra-diosensitizes tumour cells. Cancer Res. (1994) 54:4266–4269.
   PubMed Web of Science ®Google Scholar
• GO1lESMAN MM, GERMANN UA, AKSENTIJEVICH I, SUGI- MOTO Y CARDARELLI CO, PASTAN I: Gene therapy of drug resistance genes: Implications for cancer therapy. Annals New York Acad. Sci. (1994) 716:126-138. A recent review of MDR genes and their application in cancer gene therapy.
   Google Scholar
• PASTAN I, GOTTESMAN MM: Multiple-drug resistance in human cancer. New Engl. J. Med. (1987) 316:1388–1393.
   PubMed Web of Science ®Google Scholar
• SHEN DW, CARDARELLI C, HWANG j, CORNWELL MM, RICHERT N, ISHII SI, PASTAN I, GOTTESMAN MM: Multiple drug-resistant human KB carcinoma cells inde-pendently selected for high-level resistance to col-chicine, adriamycin, 'or vinblastine show changes in expression of specific proteins. J. Biol. Chem. (1986) 261:7762–7770.
   PubMed Web of Science ®Google Scholar
• RONINSON IB, CHIN JE, CHOI K, GROS P. HOUSMAN DE, FOJO A, SI IEN DW, GOTTESMAN MM, PASTAN I: Isolation of the human mdr DNA sequences amplified in mul-tidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. USA (1986) 83:4538-4542. A significant report of isolation of the human MDR I gene.
   Google Scholar
• CHEN CJ, CHIN JE, UEDA K, CLARK D, PASTAN I, GOI1ES-MAN MM, RONINSON IB: Internal duplication and ho-mology with bacterial transport protein in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47:381–389.
   PubMed Web of Science ®Google Scholar
• JURANA PF, ZASTAWNY RL, LING V: P-g,lycoprotein: Mul- tidrug-resistance and a superfamily of membrane-asso-ciated transport proteins. FASEB J. (1989) 3:2583-2592. A detailed review on multidrug-resistance and a superfamily of membrane-associated transport proteins.
   Google Scholar
• GO I1ESMAN MM, PASTAN I: Biochemistry of multidrugresistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385–427.
   PubMed Web of Science ®Google Scholar
• RIORDAN JR, DEUCI1ARS K, KARTNER N, ALON N, TRENT J, LING V: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature (1985) 316:817–819.
   PubMed Web of Science ®Google Scholar
• GROS P, NERIAH YB, CROOP JM, HOUSMAN DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (1986) 323:728–731.
   PubMed Web of Science ®Google Scholar
• SHEN DW, FOJO A, RONINSON 113, CIIIN JE, SOFFIR P, PASTAN I, GO1TESMAN MM: Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr 1 gene. Mol. Cell. Biol. (1986) 6:4039–4044.
   PubMed Web of Science ®Google Scholar
• GALSKI II, SULLIVAN M, WILLINGHAM MC, CHIN KV, GO1IESMAN MM, PASTAN I, MERLINO GT: Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: Resistance to daunomycin-induced leultopenia. Mot Cell. Biol. (1989) 9:4357-4363. A study of the MDRI transgenic mouse model.
   Google Scholar
• MORROW CS, COWAN KH: Mechanisms and clinical significance of multidrug resistance. Oncology (1988) 2:55–67.
   PubMedGoogle Scholar
• BECK WT: Mechanisms of multidrug resistance in hu-man tumour cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat. Rev. (1990) 17(Suppl. A):11–20.
   Google Scholar
• FINE RL, PATEL J, CHABNER BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA (1988) 85:582–586.
   PubMed Web of Science ®Google Scholar
• TAYLOR CW, BRATTAIN MG, YEOMAN LC: Occurrence of cytosolic protein and phosphoprotein changes in hu-man colon tumor cells with the development of resis-tance to mitomycin C. Cancer Res. (1985) 45:4422–4427.
   PubMed Web of Science ®Google Scholar
• WANG AL, TEw ICD: Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitro-gen mustards. Cancer Treat. Rep. (1985) 69:677–682.
   PubMedGoogle Scholar
• MCGOWN AT, FOX BW: A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother. Pharmacol. (1986) 17:223–227.
   PubMed Web of Science ®Google Scholar
• ROBSON CN, LEWIS AD, WOLF CR, HAYES JD, HALL A, PROCTOR SJ, HARRIS AL, HICKSON ID: Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing ele-vated glutathione-S-transferase activity. Cancer Res. (1987) 47:6022–6027.
   PubMed Web of Science ®Google Scholar
• MORROW CS, COWAN KH: Multidrug resistance associ-ated with altered topoisomerase H activity-topoisom-erase II as targets for rational drug design. J. Natl. Cancer Inst. (1990) 82:638–639.
   PubMed Web of Science ®Google Scholar
• DEFFIE AM, BATRA JK, GOLDENGERG JG: Direct correla-tion between DNA topoisomerase II activity and cyto-toxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. (1989) 49:58–62.
   PubMed Web of Science ®Google Scholar
• SAVAS B, COLE SPC, AKOGLU TF, PROSS HF: P-glycopro-teinmediated multidrug resistance and cytotoxic effec-tor cells. Nat. Immun. (1992) 11:177–192.
   PubMedGoogle Scholar
• MICKISCH GH, AKSENT1JEVICH I, SCHOENLEIN PV, GOLD-STEIN LI, GALSKI H, STAHLE C, SACIIS DH, PASTAN I, GO 11ESMAN MM: Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelo-suppressive effect of chemotherapy in mice. Blood (1992) 79:1–7.
   PubMedGoogle Scholar
• PODDA S, WARD M, HIMELSTEIN A, RICHARDSON C, FLOR-WEISS E, SMITH L, GOTTESMAN MM, PASTAN I, BANK A: Transfer and expression of the human multi-ple drug resistance (MDR) gene into live mice. Proc. Natl. Acad. Sci. USA (1992) 89:9676–9680.
   PubMed Web of Science ®Google Scholar
• SORRENTINO BP, BRANDT SJ, BODINE D, GOTTESMAN MM, PASTAN I, CLINE A, NIENHUIS AW: Retroviral trans-fer of the human MDR1 gene permits selection of drug-resistant bone marrow cells in vivo. Science (1992) 257:99-103. A significant report of in vivo selection of drug-resistant bone marrow cells after transfer with the MDR1 gene: implication for chemopre-vention.
   Google Scholar
• HANANIA EG, FU SQ, RONINSON I, ZU Z, GOTTESMAN MM, HEGEWISCH-BECKER S, ANDREEFF M, DEISSEROTH AB: Resistance to Taxol chemotherapy engineered by safety-modified retroviruses containing an MDR-1 tran-scription unit. Gene Ther. (1995). In press.
   Google Scholar
• HANANIA EG, DEISSEROTH AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy modeL Cancer Gene 7ber. (1994) 1:21–25.
   Google Scholar
• COREY CA, DESILVA AD, HOLLAND CA, WILLIAMS DA. Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood (1990) 75:337–343.
   PubMed Web of Science ®Google Scholar
• SURESH A, TUNG E, MOREB J, JAMES RZ: Role of manga-nese superoxide dismutase in radioprotection using gene transfer studies. Cancer Gene 7ber. (1994) 1:85–90.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, AEBERSOLD P, CORNETTA K, KASLD A, •MORGAN RA, MOEN R, 'ARSON EM, LOTZE MT, YANG JC,TOPALIAN SL, MERINO MJ, CULVER K, MILLER AD, BLAESE RM, ANDERSON WF: Gene transfer into humans: inunu-notherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction_ New Engl. J. Med. (1990) 323:570-578. First report of ex vivo gene transfer into human.
   Google Scholar
• BLAESE RM, ANDERSON WF: The ADA human gene therapy clinical protocoL Human GeneTher.(1990) 1:327–329.
   Google Scholar
• ROSENBERG SA, SPIESS P, LAFRENIERE II: A new approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. Science (1986) 233:1318-1321. An introduction about application of TIL for cancer therapy.
   Google Scholar
• MUUL LM, SPIESS PJ, DIRECTOR, EP, ROSENBERG SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. (1987) 138:989–995.
   PubMed Web of Science ®Google Scholar
• BARTH RJ, BOCK SN, MULE JJ, ROSENBERG SA: Unique murine tumor associated antigens identified by tumor-infiltrating lymphocytes. J. Immunol. (1990). 144:1531–1537.
   PubMed Web of Science ®Google Scholar
• BARTH RJ, MULE JJ, SPIESS PJ, ROSENBERG SA: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8* tumor-infiltrat-ing lymphocytes. J. Exp. Med. (1991). 173:647–658.
   PubMed Web of Science ®Google Scholar
• TOPALIAN SL, SOLOMON D, ROSENBERG SA: Tumor-spe-cific cytolysis by lymphocytes infiltrating human mela-noma. .1 Immunol. (1989) 142:3714–3725.
   Google Scholar
• FISHER B, PAKARD BS, READ EJ, CARRASQUILLO JA, CAR-TER CS, TOPALIAN 5, YANG JC, YOLLES P, LARSON SM, ROSENBERG SA: Tumor localization of adoptively trans-ferred Indium-111 labeled tumor infiltrating lympho-cytes in patients with metastatic melanoma. J. Clin. Oncol. (1989) 7:250–261.
   PubMed Web of Science ®Google Scholar
• GRIFFITH KD, READ EJ, CARRASQUILLO JA, CARTER CS, YANG JC, FISHER B, AEBERSOLD P, PACKARD BS, YU MY, ROSENBERG SA: In vivo distribution of adoptively trans-ferred Indium-111 labeled tumor-infiltrating lympho-cytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Nail. Cancer Inst. (1989) 81:1709–1717.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, PACKARD BS, AEBERSOLD PM, SOLO-MON D, TOPALIAN SL, TOY ST, SIMON P, LOTZE MT, YANG JC, SEIPP CA, SIMPSON C, CARTER C, BOOK S, SCHWARTZENTRUBER D, WE! JP, WHITE DE: Use of tu-mor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. New Engl. J. Med (1988) 319:1676–1680.
   PubMed Web of Science ®Google Scholar
• KASID A, MORECKI S, ABERSOLD P, CORNETTA K, CULVER K, FREEMAN S, DIRECTOR E, LOTZE MT, BLAESE RM, ANDERSON WF, ROSENBERG SA: Human gene transfer: characterization of human tumor-infiltrating lympho-cytes as vehicles for retroviral-mediated gene transfer in man. Proc. Natl. Acad. Sci. USA (1990) 87:473–477.
   PubMed Web of Science ®Google Scholar
• RILL DR, MOEN RC, BUSCHLE M, BARTHOLOMEW C, FOREMAN NK, MIRRO J, KRANCE RA, IHLE JN, BRENNER MK: An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplanta-tion using retrovirus-mediated gene transfer. Blood (1992) 79:2694–2700.
   PubMed Web of Science ®Google Scholar
• DIESSEROTH AB: Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. Human Gene 7ber. (1993) 4:71–85.
   Google Scholar
• ASHER AL, MULE JJ, REICHERT CM, SHILONI E, ROSEN-BERG SA: Studies on the anti-tumor efficacy of systemi-cally administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. (1987) 138:963–974.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Human Gene Ther. (1992) 3:57–73.
   PubMedGoogle Scholar
• ROSENBERG SA: Gene therapy for cancer. In: Important Advances in Oncology. DeVita VT, Jr., Hellman S, Rosenberg SA (Eds.). JB Lippincott Company, Philadelphia (1992):17–38.
   Google Scholar
• HWLT P, YANNELLI J, KRIEGLER M, ANDERSON WF, PEREZ C, CIIIANG Y, SCHEARZ S, COWFIERD R, DELGADO C, MULE J, ROSENBERG SA: Functional and molecular char-acterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-a cDNA for the gene therapy of cancer in humans. J. Immunol. (1993) 150:4104–4115.
   PubMed Web of Science ®Google Scholar
• ESHHAR Z: Redirection of effector lymphocytes to tu-mor cells using chimeric receptors with antibody speci-ficity. Cancer Gene Ther. (1994) 1:139.
   Google Scholar
• ESIIHAR Z, WAKS T, GROSS G, SCHINDLER D: Specific activation and targeting of cytotoxic lymphocytes through chimeric single-chains consisting of antibody-binding domains and the y or subunits of the itamu-noglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA (1993) 90:720–724.
   PubMed Web of Science ®Google Scholar
• MORITZ D, WELS W, MAll ERN J, GRONER B: Cytotoxic T-lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA (1994) 91:4318–4322.
   PubMed Web of Science ®Google Scholar
• OETTGEN HF, OLD LJ: The history of cancer immuno-therapy. In: Biologic Therapy of Cancer. DeVita VT, Hellman S, Rosenberg SA (Eds.). JB Lippincott, Philadelphia (1991):87–119.
   Google Scholar
• VAAGE J: Peritumor interleukin-2 causes systemic therapeutic effect via interferon-y induction. Int. J. Can-cer(1991) 49:598–600.
   PubMed Web of Science ®Google Scholar
• HULAND E, HULAND H, HEINZER H: Interleukin-2 by inhalation: local therapy for metastatic renal cell carci-noma. J. Urol. (1992) 147:344–348.
   PubMed Web of Science ®Google Scholar
• COLOMBO M, MODESTI A, PARMIANI G, FORNI G: Local cytokine availability elicits tumor rejection and sys-temic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. (1992) 52:4853–4857.
   PubMed Web of Science ®Google Scholar
• TEPPER RI, MULE JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Ther. (1994) 5:153-164. A detailed review on cytokine gene-modified tumor cells as tumor vaccines.
   Google Scholar
• LOTZE MT: Role of 11–4 in the antitumor response. Im IL-4: Structure and Function. Spits H (Ed.). CRC Press, Boca Raton, FL (1991) 147:2950–2956.
   Google Scholar
• TEPPER RI, PA11LNGALE PK, LEDER P: Murine inter-leukin-4 displays potent antitumor activity in vivo. Cell (1989) 57:503–512.
   PubMed Web of Science ®Google Scholar
• GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI, JAFFEE LM, KARASUYAMA H, BAKER M, PARDOLL DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254:713-716. An early study of the cytokine gene-modified tumour vaccine.
   Google Scholar
• PIPPIN BA, ROSENSTEIN M, JACOB WF, CHIANG Y, LOTZE MT: Local 11-4 delivery enhances immune reactivity to murine tumors: Gene therapy in combinantion with 11-2. Cancer Gene Ther. (1994) 1:35–42
   PubMed Web of Science ®Google Scholar
• SMITH KA: Interleukin-2: inception, impact, and impli- •cations. Science (1988) 240:1169-1176. A detailed review of IL-2.
   Google Scholar
• GRIMM EA, MAZUMDER A, ZIIANG HZ, ROSENBERG SA: Lymphokine-activated killer phenomenon. Lysis of natural killer resistant fresh solid tumor cells by inter-leukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. (1982) 155:1823–1841.
   Google Scholar
• FEARON E, PARDOLL D, ITAYA T, GOLUMBEK P, LEVITSKY H, SIMONS J, KARASUYAMA H, VOGELSTEIN B, FROST P: Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell (1990) 60:397–403.
   PubMed Web of Science ®Google Scholar
• GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNERJI R, GILBOA E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. (1990) 172:1217–1224.
   PubMed Web of Science ®Google Scholar
• BUBENIK J, SIMOVA J, JANDLOVA T: linmunotherapy of cancer using local administration of lymphoid cells expressing 11-2 cDNA and constitutively producing 11-2. Immunol. Lett. (1990) 23:287–292.
   PubMed Web of Science ®Google Scholar
• PORGADOR A, GANSBACHER B, BANNERI R, TZEIIOVAL E, GILBOA E, FELDMAN M, EISENBACH L: Anti-metastatic vaccination of tumor-bearing mice with 11-2-gene-in-serted tumor cells. Intl. Cancer (1993) 53:471–477.
   PubMed Web of Science ®Google Scholar
• TSAI SCJ, GANSBACHER B, TAIT L, MILLER FR, HEPPNER G11: Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Can-cer Inst. (1993) 85:546–553.
   PubMed Web of Science ®Google Scholar
• GANSBACHER B, ZIER K, CRONIN K, HANTZOPOULOS PA, BOUCHARD B, HOUGHTON A, GILBOA, E, GOLDE D: Retroviral gene transfer induced constitutive expres-sion of interleukin-2 or interferon-y in irradiated hu-man melanoma cells. Blood (1992) 80:2817–2825.
   PubMed Web of Science ®Google Scholar
• HADDADA H, RAGOT T, CORDIER L, DUFFOUR MT, PER-RICADUET M: Adenoviral interleukin-2 gene transfer into p815 tumor cells abrogates tumorigenicity and induces antiturnoral immunity in mice. Human Gene Ther. (1993) 4:703–711.
   PubMed Web of Science ®Google Scholar
• GASTL G, FINSTAD CL, GUARINI A, BOSL G, GILBOA E, BANDER NH, GANSBACHER B: Retroviral vector-medi-ated lymphokine gene transfer into human renal can-cer cells. Cancer Res. (1992) 52:6229–6236.
   PubMed Web of Science ®Google Scholar
• ZIER KS, SALVADORI S, CRONIN KC, GANSBACHER B: Vaccination with IL-2-secreting tumor cells stimulates the generation of 11-2-responsive T-cells and prevents the development of unresponsiveness. Cancer Gene Ther. (1994) 1:43–50.
   PubMed Web of Science ®Google Scholar
• FOA R, GUARINI A, GANSBACHER B: 11–2 treatment for cancer: from biology to gene therapy. Br.J. Cancer(1992) 66:992-998. A detailed review on IL-2 and its application for tumour vaccination.
   Google Scholar
• DALGLEISH AG: The role of 11-2 in gene therapy. Gene Ther. (1994) 1:83–87.
   PubMed Web of Science ®Google Scholar
• WALLACH D, FELLOUS M, REVEL M: Preferential effect of interferon-yon the synthesis of II1A-antigens and their mRNAs in human cells. Nature (1982) 299:833–836.
   PubMed Web of Science ®Google Scholar
• CHEN LK, TOURVIEILLE B, BURNS GF, BACH FH, MATIELJ-MAHUL D, SASPORTES M, BENSUSSAN A: Interferon-7: a cytotoxic T-lymphocyte differentiation signaL Eur. J. Immunol. (1986) 16:767–770.
   Web of Science ®Google Scholar
• NICHOLAS PR, SPIESS PJ, KARP SE, MULE JJ, ROSENBERG SA: A nonimmunogenic sarcoma transduced with cDNA for interferon-7 elicits CDS+ T-cells against the wild-type tumor: correlation with antigen presentation capabil-ity. P:xp. Med. (1992) 175:1423–1431.
   Google Scholar
• PORGADOR A, BANNERJI R, WATANABE Y, FELDMAN M, GILBOA E, EISENBACH L: Antimetastatic vaccination of tumor-bearing mice with two types of IFN-7 gene-in-serted tumor cells. J. Immunol. (1993) 150:1458–1470.
   PubMed Web of Science ®Google Scholar
• ABDEL-WAHAB ZA, OSANTO S, DARI2OW TL, BARBER JR, VERVAERT CE, GANGAVALLI R, MCCALLISTER TJ, SEIGLER HF: Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther. (1994) 1:171–179.
   PubMed Web of Science ®Google Scholar
• COLLINS T, LAPIERRE, LA, HERS W, STROMINGER JL, POBER JS: Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc. Natl. Acad. Sci. USA (1986) 83:446–450.
   PubMed Web of Science ®Google Scholar
• CARSWELL EA, OLD LJ, KASSEL RL, GREEN S, FIORE N, WILLIAMSON B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad, Sci. USA (1975) 72:3666–3670.
   PubMed Web of Science ®Google Scholar
• HARANAKA K, SATOMI N, SAKURAI A: Antitumor activity of murine tumor necrosis factor (INF) against trans-planted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer (1984) 34:263–267.
   PubMed Web of Science ®Google Scholar
• SIDIIU RS, BOLLON AP: Tumor necrosis factor activities and cancer therapy - a perspective. Pharmacol. Ther. (1993) 57:79–128.
   PubMed Web of Science ®Google Scholar
• ASIIER AL, MULE JJ, KASID A, RESTIFO NP, SALO JC, REICHERT CM, JAFFE G, FENDLY B, KRIEGLER M, ROSEN-BERG SA: Murine tumor cells transduced with the gene for tumor necrosis factor-a: Evidence for paracrine immune effects of tumor necrosis factor against tu-mors. J Immunol. (1991) 146:3227–3234.
   PubMed Web of Science ®Google Scholar
• BLANKENSTEIN T, QIN, Z, UBERLA K, MULLER W, ROSEN H, VOLK, Ill), DIAMANTSTE1N T: Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J. Exp. Med. (1991) 173:1047–1052.
   PubMed Web of Science ®Google Scholar
• KARP SE, FARBER A, SALO JC, HWU P, JAFFE G, ASILER Ai, SHILONI E, RESTTFO NR, MULE JJ, ROSENBERG SA: Cytok-ine secretion by genetically modified nortirranunogenic murine fibrosarcoma. J. Immunol. (1993) 150:896–908.
   PubMed Web of Science ®Google Scholar
• STOTTER H, CUSTER MC, BOLTON ES, GUEDEZ L, LOTZE MT: 11-7 induces human lymphokine-activated killer cell activity and is regulated by 11-4. J. Immunol. (1991) 146:50–155.
   Google Scholar
• ALDERSON MR, TOUGH TW, ZIEGLER SF, GRABSTEIN KH: Interleukin-7 induces cytokine secretion and tumorici-dal activity by human peripheral blood monocytes. J. Exp. Med. (1991) 173:923–930.
   PubMed Web of Science ®Google Scholar
• HOCK EL DORSCH M, DIAMANTSTEIN T, BLANKENSTEIN T: Interleukin-7 induces CD4+ T-cell-dependent tumor rejection. J Esp. Med. (1991) 174:1291–1298.
   Google Scholar
• MCBRIDE WET, THACKER JD, COMORA S, ECONOMOU JS, KELLY D, HOGGE D, DUBINETT SM, DOUGHERTY GJ: Genetic modification of a murine fibrosarcoma to pro-duce interleukin-7 stimulates host cell infiltration and tumor immunity. Cancer Res. (1992) 52:3931–3937.
   PubMed Web of Science ®Google Scholar
• JICIIA DL, MULE JJ, ROSENBERG SA: Interieukin-7 gener-ates antitumor CTL against murine sarcomas with effi-cacy in cellular adoptive inamunotherapy. J. Exp. Med. (1991) 174:1511–1515.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Ann. Rev. lmmunol. (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• INABA K, INABA MN, ROMANI N, AYA II. STEINMAN S: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. (1992) 176:1693–1703.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A, GOLUMBEK P, LEVIT- •SKY H, BROSE K, JACKSON V, HAMADA If, PARDOLL D,MULLIGAN R: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90:3539-3543. A signifcant report on the GM-CSFgene-modified tumour vaccination and comparison with the effects of other crokine genes.
   Google Scholar
• NICOLA NA, METCALF D, MATSUMOTO M, JOIINSON GR: Purification of a factor inducing differentiation in mur-ine myelomonocytic leukemia cells: identification as granulocyte colony-stimulating factor (G-CSF). J. Biol. Chem. (1983) 258:9017–9023.
   PubMed Web of Science ®Google Scholar
• COLOMBO MP, FERRARI G, STOPPACCIARO A, PARENZA M, RODOLFO M, MAVILIO F, PARMIANI G: Granulocyte colony-stimulating factor gene transfer suppresses tu-morigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. (1991) 173:889–897.
   PubMed Web of Science ®Google Scholar
• COLOMBO MP, LOMBARDI L, STOPPACCIARO A, MELANI C, PARENZA M, BOTTAZZI B, PARMIANI G: Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: neutrophiLs discriminate be-tween G-CSF-producing and G-CSF-nonproducing tu-mor cells.]. Immunol. (1992) 149:113–119.
   PubMed Web of Science ®Google Scholar
• STOPPACCIARO A, MELANI C, PARENZA M, MASTRACCHIO A, BASSI C, BARONI C, PARMIAN1 G, COLOMBO MP: Regression of an established tumor genetically modi-fied to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T-cell-pro-duced interferon-y. J. Exp. Med. (1993) 178:151–161.
   PubMed Web of Science ®Google Scholar
• OSTRAND-ROSENBERG S. THAKUR A, CLEMENTS V: Rejec-tion of mouse sarcoma cells after transfection of MHC class II gene. J. Immunol. (1990) 144:4068–4071.
   PubMed Web of Science ®Google Scholar
• SCHULTZ Z, KLARNET J, GIENI R, HAYGLASS K, GREEN-BERG P: The role of B-cells for in vivo T-cell responses to a Friend virus-induced leukemia. Science (1990) 249:921–923.
   PubMed Web of Science ®Google Scholar
• GREENBERG PD: Adoptive T-cell therapy of tumors: Mechanisms operative in the recognition and elimina-tion of tumor cells. Adv. Immunol. (1990) 49:281–355.
   Web of Science ®Google Scholar
• MUELLER D, JENKINS M, SCIIWARTZ R: Clonal expansion versus function clonal inactivation: a co-stimulatory signalling pathway determines the outcome of T-cell antigen receptor occupancy. Ann. Rev. Immunol. (1989) 7/145–480.
   Google Scholar
• GIMMI CD, FREEMAN GJ, GRIBBEN JG, SUGITA K, FREED-MAN AS, MORIMOTO C, NADLER LM: B-cell surface anti–217 • gen B7 provides a costimulatory signal that induces T-cells to proliferate and secrete interleulcin 2. Proc. Natl. Acad. Sci. USA (1991) 88:6575–6579.
   Google Scholar
• KOULOVA L, CLARK E, SHU G, DUPONT B: The CD28 ligand B7/BB1 provides a co-stimulatory signal for alloactivation of CD4+ T-cells. J. Exp. Med. (1991) 173:759–762.
   PubMed Web of Science ®Google Scholar
• LINSLEY P, BRADY W, URNES M, GROSMAIRE L, DAMLE N, LEDBE IIER J: CTLA-4 is a second receptor for the B-cellactivation antigen B7. J. Exp. Med. (1991) 174:561–569.
   PubMed Web of Science ®Google Scholar
• RAZI-WOLF Z, FREEMAN G, GALVIN F, BENACERRAF B, NADLER L, REISER H: Expression and function of the murine 137 antigen, the major co-stimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA (1992) 89:4210–4214.
   PubMed Web of Science ®Google Scholar
• NABAVI N, FREEMAN G, GAULT A, GODFREY D, NADLER L, GLIMCHER L: Signaling through the MHC class II cytoplasmic domain is required for antigen presenta-tion and induces B7 expression. Nature (1992) 360:266–268.
   PubMed Web of Science ®Google Scholar
• HUT K, GROSVELD F, FESTENSTEIN H: Rejection of trans-plantable AKR leukaemia cells following MHC DNA-me-diated cell transformation. Nature (1984) 311:750–752.
   PubMed Web of Science ®Google Scholar
• WALLICH R, BULBUC N, HAMMERLING G, KATZAV S, SEGAL S, FELDMAN M: Abrogation of metastatic proper-ties of tumor cells by de novo expression of II-2K antigens following II-2 gene transfection. Nature (1985) 315.301–305
   PubMed Web of Science ®Google Scholar
• FREEMAN GJ, FREEDMAN AS, SEGIL JM, LEE G, WHITMAN JF, NADLER LM: B7, a new member of the Ig superfamily with the unique expression on activated and neoplastic B-cells. J. Immunol. (1989) 143:2714–2722.
   PubMed Web of Science ®Google Scholar
• FREEMAN GJ, GRIBBEN JG, BOUSSIOTIS VA, NG JW, RES-TIVO VA, LOMBARD LA, GRAY GS, NADLER LM: Cloning of B7-2: a CTLA4 counter-receptor that costimulates human T-cell proliferation. Science (1993) 262:909–911.
   PubMed Web of Science ®Google Scholar
• CHEN L, ASHE S, BRADY W, IIELLSTROM I, HELLSTROM RE, LEDBETTER J, MCGOWAN P, LINSLEY P: Co-stimula-tion of antitumor immunity by the B7 counter-receptor for the T-Iymphocyte molecules CD28 and CTLA-4. Cell (1992) 71:1093-1102. A significant study of the B7 co-stimulatory effect on antitumour immunity.
   Google Scholar
• TOWNSEND S, ALLISON J: Tumor rejection after direct co-stimulation of CD8+ T-cells by B7-transfected mela-noma cells. Science (1993) 259:368-370. A significant study of the B7 gene-modified tumour vaccine.
   Google Scholar
• BASKAR S, NABAVI N, GILMCHER LH, OSTRAND-ROSEN-BERG S: Tumor cells expressing major histocompatibil-ity complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immuno-therapy (1993) 14:209–215.
   PubMed Web of Science ®Google Scholar
• BASKAR S, OSTRAND-ROSENBERG S, NA13AVI N, NADLER L, GILMCHER LIT: Constitutive expression of B7 restores inununogenicity of tumor cells expressing truncated MHC class II molecules. Proc. Natl. Acad. Sci. USA (1993) 90:5687–5690.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, GRIMM EA, MUKHOPADIIYAY T, ZHANG WW, OWEN-SCHAUB LB, ROTH JA: Induction of che-mosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. (1994) 54:2287–2291.
   PubMed Web of Science ®Google Scholar
• LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA, JACKS T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 362:847–849.
   PubMed Web of Science ®Google Scholar
• HU G, LIU W, HANANIA EG, FU S, WANG T, DEISSEROTTI AB: Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of human papilloma virus and the sense mRNA for the retinoblas-totna gene in cervical carcinoma cells. Cancer Gene Ther. (1995) 2:19–32.
   PubMed Web of Science ®Google Scholar
• OHIRA T, ODE Y, HEIKE Y, PODACK ER, OLSEN KJ, NISHIO K, NISHIO M, MIYAHARA Y, FUNAYAMA Y, OGASAWARA H, ARIOKA H, KATO H, SAVO N: Gene therapy for Lewis lung carcinoma with tumor necrosis factor and inter-leukin 2 cDNAs co-transfected sublime. Gene Ther. (1994) 1:269–275.
   PubMed Web of Science ®Google Scholar
• CASTLEDEN S, HELSON JA, CHONG H, I IART I, VILE RG: The use of combination gene therapies for the treat-ment of cancer. J. Cell. Biochem. (1995) 21(Suppl. A):418.
   Google Scholar
• CHIN SD, CHEN XH, KOSAIL III, WANG Y, FINEGOLD MJ, RICH SS, WOO SLC: Combination suicide and cytokine gene therapy for metastatic colon carcinoma in vivo. J. Cell. Biochem. (1995) 21(Suppl. A):419.
   Google Scholar